| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.22 | 1e-06 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.18 | 0.0002 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.16 | 0.001 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.001 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.17 | 0.001 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.16 | 0.003 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.003 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |